Weishi Pharmaceutical

Weishi Pharmaceutical (officially Weishi (Shanghai) Pharmaceutical Technology) is a clinical-stage biotechnology company focused on developing innovative immunotherapy treatments for allergic diseases. Headquartered in Shanghai, the company specializes in allergen-specific immunotherapy (ASIT) using its proprietary Particulate Carrier Unit (PCU) technology to enhance the safety and efficacy of treatments. Its pipeline includes candidates for allergic rhinitis and asthma triggered by dust mites, mugwort, and birch pollen, as well as treatments for food allergies. In 2021, Weishi was acquired by Worg Pharmaceuticals, a move that combined Weishi's specialized allergy portfolio with Worg's global development capabilities. The company's lead program, WP-1048, is currently in clinical development for the treatment of dust mite-induced allergic rhinitis. Weishi's approach aims to provide disease-modifying solutions that address the underlying causes of allergies rather than just managing symptoms.